New options for the management of chronic hyperkalemia

Area of Science:

• Nephrology
• Internal Medicine
• Clinical Pharmacology

Background:

• Hyperkalemia is a common electrolyte disorder with potentially fatal consequences.
• Intrinsic factors (e.g., reduced glomerular filtration rate, impaired mineralocorticoid activity) and extrinsic factors (e.g., medications, dietary potassium) contribute to hyperkalemia.
• The widespread use of renin-angiotensin-aldosterone system inhibitors in susceptible populations increases hyperkalemia incidence.

Purpose of the Study:

• To review the causes of hyperkalemia.
• To discuss current and emerging strategies for managing hyperkalemia.
• To highlight the impact of new potassium-binding agents on hyperkalemia treatment.

Main Methods:

• Literature review of hyperkalemia causes and treatments.
• Analysis of the role of intrinsic and extrinsic factors in hyperkalemia development.
• Evaluation of recent advancements in pharmacologic management of hyperkalemia.

Main Results:

• Hyperkalemia results from complex interactions between kidney function, hormonal activity, metabolic status, and medication use.
• Renin-angiotensin-aldosterone system inhibitors are significant contributors to hyperkalemia in patients with comorbidities.
• Two novel oral potassium binders represent a significant advancement in hyperkalemia management.

Conclusions:

• Understanding the multifactorial etiology of hyperkalemia is crucial for effective patient care.
• Optimizing treatment strategies, including the use of new potassium binders, is essential for managing hyperkalemia.
• The advent of new oral potassium binders signifies a paradigm shift in hyperkalemia treatment, improving patient outcomes.